✦ LIBER ✦

Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study

✍ Scribed by Nicola De Stefano; Maria Pia Sormani; Bettina Stubinski; Gregg Blevins; Jelena S. Drulovic; Delphine Issard; Penko Shotekov; Claudio Gasperini

Book ID: 119304252
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 369 KB
Volume: 312
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2011.08.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab versus interferon beta-1a in

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

✍ Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzys 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 306 KB

PND8 COST-EFFECTIVENESS AND BUDGET IMPAC

PND8 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

✍ O Espallardo; C Crespo; C Polanco; D Nieves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Comparison of fingolimod with interferon

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

✍ Bhupendra Khatri; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Ludwig K 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 228 KB

The long-term safety and tolerability of

The long-term safety and tolerability of high-dose interferon β-1a in relapsing–remitting multiple sclerosis: 4-year data from the PRISMS study

✍ R. Gold; P. Rieckmann; P. Chang; J. Abdalla; the PRISMS Study Group 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Longitudinal changes in social functioni

Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)

✍ Francesco Patti, Maria Pia Amato, Maria Trojano, Stefano Bastianello, Maria Rosa 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 285 KB